Should patients with lone atrial fibrillation be treated with anticoagulant therapy?  by Lui, Charles Y.
JACC Vol. 18. No. I 
July 1991:301-2 
Editorial Comment 
Should Patients With Lone Atrial 
Fibrillation Be Treated With 
Anticoagulant Therapy?* 
CHARLES Y. LUI, MD, FACC 
Salem, Virginia 
Although it is clinically well recognized that patients with 
atrial fibrillation and organic heart disease have a markedly 
increased embolic risk, it is far less certain whether a lower 
risk is involved in patients with lone atrial fibrillation. 
Kumagai et al. (1) recently reported a comparable increase in 
D-dimer level in patients with lone atrial fibrillation and 
those with structural heart disease, indicating a similar 
increase in intracardiovascular clotting state in the two 
groups. This interesting finding leads one to suspect that 
patients with lone atrial fibrillation may have an increased 
risk of thromboembolism equal to that of patients with 
structural heart disease. If this is the case, both groups of 
patients should be treated with anticoagulant therapy. 
Previous reports on the incidence of thromboembolic 
stroke in lone atrial fibrillation contradict one another. The 
1985 population-based Framingham study demonstrated a 
more than 5-fold increase in embolic stroke in lone atrial 
fibrillation (2.6%/year), as opposed to an 18-fold increase in 
those with rheumatic heart disease (2,3). A later report from 
the Mayo Clinic, another population-based study (4), 
showed a much lower risk of stroke (0.55%/year). The 
reason for the conflicting results is not apparent, although 
the Mayo data were derived retrospectively and patients 
from the Framingham study were much older and 32% of 
them had preexisting hypertension. A more recent report by 
Shimomura et al. (5) indicated an embolic rate of l.5%/year. 
However, it is not a population-based study and 29% of the 
patients had either hypertension, hypertensive heart disease 
or thyroid disease. Two latest multicenter trials (6,7) again 
showed somewhat contrasting data: the Boston Area Anti-
coagulation Trial for Atrial Fibrillation Investigators (6) 
reported a 1.3%/year incidence of stroke, and the prelimi-
nary report of the Stroke Prevention in Atrial Fibrillation 
Study Group Investigators (7) showed a zero incidence at a 
mean follow-up of a little over a year. Unfortunately, in the 
former study 95% of the lone atrial fibrillation group had 
'Editorials published in Journal of the American College of Cardiology 
reflect the views of the authors and do not necessarily represent the views of 
JACC or the American College of Cardiology. 
From the Cardiac Catheterization Laboratory, Veterans Affairs Medical 
Center, Salem, Virginia. 
Address for reprints: Charles Y. Lui, MD, Cardiac Catheterization 
Laboratory, Veterans Affairs Medical Center, Salem, Virginia 24153. 
©1991 by the American College of Cardiology 
301 
either left atrial enlargement, mitral annular calcification or 
mitral regurgitation. In the latter study half of the patients 
received 325 mg of aspirin daily. 
Taking into account these study limitations, the weighed 
evidence suggests a much lower incidence of stroke in 
patients with lone atrial fibrillation. How then can one 
reconcile the lower incidence of stroke in this group with the 
finding of an increased intracardiovascular clotting state 
similar to that of patients with organic heart disease? 
First, the method of D-dimer determination employed by 
Kumagai et al. (1) is an extremely sensitive and specific 
assay. Thus, the increased D-dimer level truly reflects an 
increased clotting state in both groups. Obviously, this 
cannot be interpreted to mean an equally increased embolic 
rate in either group because many hemostatic factors (8) are 
involved in the coagulation system and other clinical varia-
bles also play a role in systemic embolization. Apart from 
this, the study of Kumagai et al. (1) is small, not popUlation 
based and therefore subject to selection biases: 4 of the 24 
patients with lone atrial fibrillation had a history of an 
embolic event and the D-dimer level is higher in patients 
with than in those without a positive history of embolization, 
although the difference does not reach statistical signifi-
cance. 
Second, several abstracts and articles published within 
the past 2 years provide insightful findings that help explain 
the present dilemma. Left atrial size gradually increases in 
lone atrial fibrillation and this suggests that the arrhythmia 
itself is a direct cause of left atrial enlargement (9,10). 
Because a larger left atrium in patients with both atrial 
fibrillation and mitral valve disease carries an increased 
thromboembolic risk (11), can such a cause and effect 
relation also exist between an enlarging left atrium and an 
increased risk ofthromboembolism in lone atrial fibrillation? 
Such a relation would be in agreement with the Framingham 
and Mayo data showing, respectively, that stroke events 
occurred at a mean of 8.5 years of follow-up and 12.3 years 
after the onset of atrial fibrillation. Because left atrial dimen-
sion is not reported by Kumagai et al. (1), it is not known 
whether left atrial enlargement is associated with an elevated 
level of D-dimer in these patients with atrial fibrillation. 
Left atrial spontaneous contrast echo was shown to be 
associated with an increased risk of stroke in both valvular 
and nonvalvular atrial fibrillation (11,12). Although it is 
logical to assume that left atrial spontaneous contrast echoes 
may lead to an increased D-dimer level as a result of 
increased turbulence within the left atrium, it remains to be 
confirmed if such a mechanism operates in the lone atrial 
fibrillation group. Alternatively, atrial fibrillation alone may 
account for the elevated D-dimer level. 
Finally, with recent advances in cardiac imaging, it has 
become evident that patients with lone atrial fibrillation in 
previous studies were not well defined. All were identified 
clinically with or without transthoracic echocardiography. 




identify many atrial structural abnormalities that are missed 
by transthoracic echocardiography (13,14). Cine computed 
tomography has also demonstrated in lone atrial fibrillation a 
high incidence of structural abnormalities undetected by 
transthoracic echocardiography (15). Therefore, some of the 
patients with lone atrial fibrillation from previous studies 
may actually have underlying cardiac abnormalities, a 
finding that may account for the observed increase in D-
dimer levels (1) and the different embolic rates reported 
(2-7). 
Conclusions. There is growing evidence to suggest that 
patients with true lone atrial fibrillation may have a much 
lower embolic risk than previously presumed. Hence, it 
becomes less clear than before regarding the need for 
anticoagulant therapy in these patients, especially since two 
multicenter stroke prevention trials (6,16) have demon-
strated that low dose, long-term warfarin is safe and effica-
cious in preventing stroke in patients with nonrheumatic 
atrial fibrillation. The preliminary report of the Stroke Pre-
vention Atrial Fibrillation Study (7) also shows a 49% 
reduction of stroke with aspirin (325 mg/day) alone in such 
patients -£75 years of age. Because this study is still ongoing, 
the relative merits of warfarin and aspirin in stroke preven-
tion in lone atrial fibrillation remain unknown. Whatever the 
outcome might be, additional studies are needed to identify 
subsets of patients with lone atrial fibrillation who may 
benefit from prophylactic anticoagulant therapy either be-
cause of its paroxysm, an advanced age, left atrial abnor-
malities, an increased clotting state or other unrecognized 
factors that predispose them to an increased risk of embo-
lism. 
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